Ritonavir contraindications: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Ritonavir }} {{CMG}}; {{AE}} {{chetan}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NORVIR (RITONAVIR) CAPSULE [ABBVIE INC.] | ur...") |
|||
| (2 intermediate revisions by the same user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{chetan}} | {{CMG}}; {{AE}} {{chetan}} | ||
==Contraindications== | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NORVIR (RITONAVIR) CAPSULE [ABBVIE INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=13b059c6-0c6c-49a5-b985-a4b05caf9ac9 | publisher = | date = | accessdate = }}</ref> | *When co-administering NORVIR with other [[protease inhibitors]], see the full prescribing information for that protease inhibitor including contraindication information. | ||
*NORVIR is contraindicated in patients with known hypersensitivity (e.g., [[toxic epidermal necrolysis]] (TEN) or [[Stevens-Johnson syndrome]]) to ritonavir or any of its ingredients. | |||
*Co-administration of NORVIR with several classes of drugs (including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations) is contraindicated and may result in potentially serious and/or life-threatening adverse events due to possible effects of NORVIR on the hepatic metabolism of these drugs (see Table 1). [[Voriconazole]] and [[St. John’s Wort]] are exceptions in that co-administration of NORVIR and voriconazole results in a significant decrease in plasma concentrations of voriconazole, and co-administration of NORVIR with St. John’s Wort may result in decreased ritonavir plasma concentrations.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NORVIR (RITONAVIR) CAPSULE [ABBVIE INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=13b059c6-0c6c-49a5-b985-a4b05caf9ac9 | publisher = | date = | accessdate = }}</ref> | |||
{| | |||
|- | |||
| [[File:|800px|thumb]] | |||
|- | |||
|} | |||
==References== | ==References== | ||
Latest revision as of 17:34, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Contraindications
- When co-administering NORVIR with other protease inhibitors, see the full prescribing information for that protease inhibitor including contraindication information.
- NORVIR is contraindicated in patients with known hypersensitivity (e.g., toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome) to ritonavir or any of its ingredients.
- Co-administration of NORVIR with several classes of drugs (including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations) is contraindicated and may result in potentially serious and/or life-threatening adverse events due to possible effects of NORVIR on the hepatic metabolism of these drugs (see Table 1). Voriconazole and St. John’s Wort are exceptions in that co-administration of NORVIR and voriconazole results in a significant decrease in plasma concentrations of voriconazole, and co-administration of NORVIR with St. John’s Wort may result in decreased ritonavir plasma concentrations.[1]
| [[File:|800px|thumb]] |
References
Adapted from the FDA Package Insert.